QN QNCX Quince Therapeutics, Inc. Loading... : Bullish and Bearish Analyst Opinions

The author views QNCX as a story stock that has so far failed to deliver financial results, describing it as swimming in uncertainty despite being early stage. Citing Buffett's four factors (how much you put in, take out, when, and with what certainty), the author implies the risk/reward is unattractive. No specific catalyst or timeline was given.

The author argues QNCX's LAM-001 addresses an unmet need in reaching deep lung tissue for transplant patients, with a once-daily formulation requiring no medical supervision and vocal endorsement from top US transplant surgeons who say such a treatment has been needed for a decade. They cite improved lung function data post-transplant, financing runway until 2028, and completed dilution as supporting factors. Downside is seen near $20 with upside potentially around $185, though the author frames this as an unchecked personal estimate rather than a firm target.

The author argues QNCX's LAM-001 addresses an unmet need in reaching deep lung tissue with a once-daily formulation requiring no medical supervision, and has been vocally endorsed by top US transplant surgeons as something needed for over a decade. They cite improved lung function data post-transplant, a runway financed until 2028, and completed dilution as supporting a potential move toward roughly $185 versus downside around $20. The main stated risk is downside to $20, and they suggest layering in as a starting position.

Author argues Quince Therapeutics' LAM-001 (inhaled rapamycin via mTOR delivery) addresses severe unmet needs in post-lung-transplant BOS, PH-ILD, and SAPH, with data showing reversal of BOS and no existing options for declined lung function. The catalyst is phase data expected throughout 2027 and 2028, with operational runway until 2028. Main risk is clinical trial failure or delay, though the author does not explicitly state this.

Author argues Quince Therapeutics' LAM-001 (inhaled rapamycin via mTOR delivery) addresses severe unmet needs in post-lung-transplant BOS, PH-ILD, and SAPH, with data showing reversal of BOS and no existing options for declined lung function. The catalyst is phase data expected throughout 2027 and 2028, with operational runway until 2028. Main risk is clinical trial failure or delay, though the author does not explicitly state this.